Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Фундаментальные метрики Humana Inc. показывают неоднозначную картину. Мультипликаторы, такие как P/E и P/S, значительно ниже медианы отрасли, что может указывать на потенциальную недооцененность компании. Однако, стоит отметить, что EPS остается отрицательным и значительно ниже медианы, что вызывает опасения относительно прибыльности. Долговая нагрузка компании выше медианы, что также является негативным фактором, так как это может увеличить финансовые риски. Дивиденды не выплачиваются, что может быть сигналом о проблемах с денежными потоками. Тем не менее, выручка компании демонстрирует рост, и она значительно превышает медианные значения по отрасли, что говорит о сильной позиции на рынке. В целом, несмотря на некоторые положительные аспекты, такие как высокая выручка и низкие мультипликаторы, уровень долговой нагрузки и отрицательные показатели прибыли создают значительные риски для инвесторов, что требует корректировки целевого ценового прогноза.

Humana Inc.

Humana Inc. HUM reported first-quarter 2026 adjusted earnings of $10.31 per share, which beat the Zacks Consensus Estimate by 3.5%. However, the bottom line fell 11% year over year.
Revenues improved 23.5% year over year to $39.6 billion. The top line surpassed the consensus mark by 0.5%.
The quarterly results benefited on the back of premium gains and a robust performance from the CenterWell segment, which saw a revenue jump supported by its primary care business. A rise in overall medical membership also contributed to the upside. However, the upside was partly offset by escalating operating expenses and a deteriorating benefit ratio.
Humana Inc. Price, Consensus and EPS Surprise
HUM’s Q1 Operational Update
Humana’s premiums totaled $37.7 billion, which advanced 23.6% year over year, and surpassed the Zacks Consensus Estimate of $37.3 billion and our estimate of $36.6 billion. Services revenues rose 25.7% year over year to $1.7 billion, beating the consensus mark of $1.6 billion. Investment income of $262 million fell 0.8% year over year in the quarter under review. However, the metric beat the consensus mark of $230 million and our estimate of $235.7 million.
The benefit ratio came in at 89.4%, which deteriorated 240 basis points (bps) year over year. Total operating expenses increased 25.9% year over year to $37.9 billion, higher than our estimate of $36.6 billion. The year-over-year increase was due to higher benefits and operating costs. The adjusted operating cost ratio of 10% improved 50 bps year over year.
HUM’s net income declined 4.7% year over year to $1.2 billion but beat our estimate of $1.1 billion.
Q1 Segmental Update of HUM
Insurance
The segment’s revenues rose 23% year over year to $38.1 billion in the first quarter on the back of improved per-member premiums derived from HUM’s Medicare and stand-alone PDP businesses, supported by improved Medicare Advantage benchmark funding from the Centers for Medicare and Medicaid Services and a higher Part D direct subsidy tied to the IRA.
Adjusted operating income dropped 8.8% year over year to $1.4 billion. The benefit ratio deteriorated 200 bps year over year to 89.4%. The operating cost ratio of 7.3% improved 90 bps year over year.
Total medical membership of the segment was 17.7 million as of March 31, 2026, which rose 19.4% year over year. The metric beat the Zacks Consensus Estimate of 16.7 million and our estimate of 15.7 million.
CenterWell
The unit recorded revenues of $6.1 billion in the quarter under review, which improved 19.7% year over year and surpassed the Zacks Consensus Estimate of $5.8 billion. The metric benefited from higher revenues stemming from the company’s primary care business.
Adjusted operating income dropped 25.1% year over year to $338 million. The operating cost ratio of 94.5% deteriorated 340 bps year over year due to the ongoing implementation of the v28 risk model update within the company’s primary care business and higher volumes in CenterWell Specialty Pharmacy.
Humana’s Financial Update (As of March 31, 2026)
Humana exited the first quarter with cash and cash equivalents of $5 billion, which rose 17.9% from the 2025-end level. Total assets of $55.3 billion increased 13% from the figure at 2025-end.
Long-term debt amounted to $12.3 billion, down 0.8% from the figure as of Dec. 31, 2025. Debt to capitalization deteriorated 190 bps year over year to 43% at the first-quarter end.
Total stockholders’ equity of $18.6 billion advanced 5.2% from the 2025-end figure.
HUM generated net cash from operations of $1.3 billion in the first quarter of 2026, which increased nearly fourfold year over year.
HUM’s Capital Deployment Update
Humana bought back shares worth $107 million in the first quarter of 2026. It also paid dividends of $107 million during the same quarter.
2026 View by HUM
Revenues are still projected to be a minimum of $160 billion, which implies a 23.4% increase from the 2025 reported figure. The Insurance segment’s revenues are expected to continue to be forecasted at a minimum of $155 billion. Revenues of the CenterWell segment are still expected to be at a minimum of $25 billion.
Adjusted EPS is still projected to be at least $9.00, which indicates a 47.5% decline from the 2025 figure. GAAP EPS is now projected to be at least $8.36, down from the previously expected guidance of at least $8.89.
Management still anticipates Individual Medicare Advantage membership to witness growth of around 25% in 2026. Group Medicare Advantage membership is still expected to record an increase of roughly 150,000.
Membership from the Individual Medicare stand-alone PDP is still expected to increase around 1,000,000 this year. State-based contracts are still anticipated to witness membership growth within 25,000-100,000.
The GAAP benefit ratio for the Insurance segment is still likely to be 92.75%, with a variability margin of plus or minus 25 basis points. The GAAP consolidated adjusted operating cost ratio is still expected to be at 10%, with a variability margin of plus or minus 25 basis points.
GAAP cash flow from operations is still estimated within $2.5-$2.9 billion. Meanwhile, capital expenditures are still projected to be roughly $650 million. The adjusted effective tax rate is expected to be around 25.5%, while the weighted average share count is anticipated at around 121 million.
HUM’s Zacks Rank
HUM currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
How Did Peers Perform?
Several companies in the Medical space, including Molina Healthcare Inc. MOH, UnitedHealth Group Incorporated UNH and Elevance Health, Inc. ELV, have already reported their financial results for the March quarter of 2026. Here’s how they had performed:
Molina Healthcare reported first-quarter 2026 adjusted earnings per share of $2.35, which beat the Zacks Consensus Estimate of $1.57. The bottom line declined 61.3% from the year-ago period's level. Revenues amounted to $10.8 billion, which decreased 3.1% year over year. The top line of Molina Healthcare marginally missed the consensus mark by 0.2%. The first-quarter performance was supported by lower medical care costs, partially offset by declining premiums, membership and investment income.
UnitedHealth reported first-quarter 2026 EPS of $7.23, which beat the Zacks Consensus Estimate of $6.46. The bottom line rose 0.4% year over year. Revenues rose 2% year over year to $111.7 billion. The top line beat the consensus mark by 2.1%. The strong quarterly earnings were aided by growth in commercial fee-based membership and the strength witnessed in Optum Rx. However, weakness in UnitedHealth’s Optum Health and declining risk-based membership partially offset the positives.
Elevance Health reported first-quarter 2026 adjusted earnings per share of $12.58, which surpassed the Zacks Consensus Estimate by 17.8%. The bottom line rose 5.1% year over year. Operating revenues advanced 1.5% year over year to $49.5 billion. The top line beat the consensus mark by 3.7%. The strong quarterly results benefited on the back of strong growth in premiums. Segment-wise, the Carelon division posted a robust revenue surge, aided by scaling risk-based services, while Health Benefits saw increased premium yields. However, Elevance Health’s upside was partly offset by a decline in overall medical membership and an elevated expense level.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Humana Beats Q1 Earnings Estimates on Increasing Premiums

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Humana (HUM) Q1 2026 Earnings Call Transcript

Humana (HUM) came out with quarterly earnings of $10.31 per share, beating the Zacks Consensus Estimate of $9.97 per share. This compares to earnings of $11.58 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.46%. A quarter ago, it was expected that this health insurer would post a loss of $4.01 per share when it actually produced a loss of $3.96, delivering a surprise of +1.25%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Humana, which belongs to the Zacks Medical - HMOs industry, posted revenues of $39.65 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.51%. This compares to year-ago revenues of $32.11 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Humana shares have lost about 10.3% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for Humana?
While Humana has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Humana was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.15 on $40.45 billion in revenues for the coming quarter and $9.09 on $162.64 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
The Joint Corp. (JYNT), another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.
This company is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of +200%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
The Joint Corp.'s revenues are expected to be $14.01 million, up 7.1% from the year-ago quarter.
Should You Invest in Humana Inc. (HUM)?
Before you invest in Humana Inc. (HUM), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Humana (HUM) Beats Q1 Earnings and Revenue Estimates

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ArcBest Corp (Symbol: ARCB), where a total of 3,081 contracts have traded so far, representing approximately 308,100 underlying shares. That amounts to about 106.1% of ARCB's average daily trading volume over the past month of 290,510 shares. Especially high volume was seen for the $125 strike call option expiring May 15, 2026, with 1,597 contracts trading so far today, representing approximately 159,700 underlying shares of ARCB. Below is a chart showing ARCB's trailing twelve month trading history, with the $125 strike highlighted in orange:
Humana Inc. (Symbol: HUM) saw options trading volume of 17,593 contracts, representing approximately 1.8 million underlying shares or approximately 99.8% of HUM's average daily trading volume over the past month, of 1.8 million shares. Especially high volume was seen for the $250 strike call option expiring May 01, 2026, with 1,599 contracts trading so far today, representing approximately 159,900 underlying shares of HUM. Below is a chart showing HUM's trailing twelve month trading history, with the $250 strike highlighted in orange:
And Delek US Holdings Inc (Symbol: DK) saw options trading volume of 10,079 contracts, representing approximately 1.0 million underlying shares or approximately 82.5% of DK's average daily trading volume over the past month, of 1.2 million shares. Particularly high volume was seen for the $40 strike put option expiring May 15, 2026, with 5,010 contracts trading so far today, representing approximately 501,000 underlying shares of DK. Below is a chart showing DK's trailing twelve month trading history, with the $40 strike highlighted in orange:
For the various different available expirations for ARCB options, HUM options, or DK options, visit StockOptionsChannel.com.
Also see:
Cheapest Stocks Right Now
Institutional Holders of RNAC
Analyst Least Favorites
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Tuesday Option Activity: ARCB, HUM, DK

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.01%. June E-mini S&P futures (ESM26) rose +0.14%, and June E-mini Nasdaq futures (NQM26) fell -0.02%.
Stock indexes settled mostly higher on Monday, with the S&P 500 and Nasdaq 100 posting new all-time highs. Optimism that demand for AI-infrastructure will remain strong and continue to power technology earnings boosted stocks on Monday. The megacap technology stocks of Alphabet, Apple, Amazon.com, Microsoft, and Meta Platforms all report quarterly earnings this week.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
The broader market saw some downward pressure from Monday’s +2% rally in WTI crude oil prices, which raised inflation expectations. Crude oil prices jumped after President Trump on Saturday canceled planned negotiations with Iran in Pakistan, saying Iran "offered a lot, but not enough" to continue negotiations. Iranian President Pezeshkian said Iran won't enter "imposed negotiations under threats or blockade." Secretary of State Rubio said Iran still wants to retain control of the Strait of Hormuz, and that was "unacceptable" to the US.
However, AI-infrastructure stocks found support on Monday after TF International Securities said that Qualcomm is working with OpenAI and Taiwan’s MediaTek to develop smartphone processors. Also, Micron Technology and SanDisk both received buy ratings from Melius Research. In addition, strength in health insurers was a positive factor for the market.
Stock indexes found support from the Axios report that Iran has given the US a new proposal to reopen the Strait of Hormuz and end the war, which includes postponing nuclear negotiations. The plan calls for extending the ceasefire so the parties can work toward a permanent end to the war, and nuclear talks would come later, only after a US blockade of the strait is lifted. The White House said Monday afternoon that President Trump is discussing the proposal with national security and foreign policy officials.
The US and Iran are locked in a battle for control of the Strait of Hormuz, with both sides blocking the waterway to gain leverage during an extended ceasefire. The US increased pressure on Iran with its naval blockade as it seeks to get Iran to agree to talks, while Israel and Lebanon are set to extend a ceasefire for three weeks.
WTI crude oil prices (CLM26) rose by more than +2% on Monday after President Trump canceled a planned weekend trip by US envoys to Pakistan and Iran said it won’t negotiate while the US naval blockade of Iran remains in force. The Strait of Hormuz remains essentially closed, threatening to deepen the global energy crisis. The ongoing blockade could exacerbate global oil and fuel shortages, as about a fifth of the world’s oil and liquefied natural gas transits through the strait. Goldman Sachs estimates that crude output in the Persian Gulf has been curtailed by about 14.5 million bpd, or more than 50%, so far in April, and that the current disruption has drawn down nearly 500 million bbl from global crude stockpiles, which could hit a billion bbl by June.
Kevin Warsh now appears to be on a glide path toward Senate approval as the new Fed Chair after Senator Thom Tillis said on Sunday that he dropped his opposition to the nomination. Mr. Tillis dropped his opposition after the US Justice Department dropped its criminal investigation into the Fed’s overspending on the renovation of its building, in line with Mr. Tillis’ demand. Mr. Tillis views the investigation into Fed Chair Powell as an attempt to force the Fed to cut interest rates. The Senate Banking Committee is due to vote on Mr. Warsh’s appointment this Wednesday and then send the nomination to the full Senate for a vote.
The markets are discounting a 0% chance for a +25 bp FOMC rate hike at the Tue-Wed policy meeting. The markets are expecting the FOMC to leave policy unchanged this week as it awaits further developments in oil prices and inflation.
Earnings season ramps up this week with several Magnificent Seven technology stocks reporting. Earnings results thus far have been supportive of stocks. As of Monday, 80% of the 139 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
Overseas stock markets settled mixed on Monday. The Euro Stoxx 50 closed down -0.39%. China's Shanghai Composite closed up +0.16%. Japan's Nikkei Stock 225 rallied to a new record high and closed up +1.38%.
Interest Rates
June 10-year T-notes (ZNM6) on Monday closed down -6 ticks. The 10-year T-note yield rose +3.6 bp to 4.337%. June T-notes retreated on Monday due to the +2% increase in the price of WTI crude oil, which boosts inflation expectations. The 10-year breakeven inflation rate rose to a 14-month high of 2.457% on Monday. Supply pressures also weighed on T-note prices, as the Treasury auctioned $69 billion of 2-year T-notes and $70 billion of 5-year T-notes.
Demand for Monday’s Treasury auctions was mixed. The 2-year T-note auction saw decent demand, with a bid-to-cover ratio of 2.65, above the 10-auction average of 2.60, while demand for the 5-year T-note auction was tepid, with a bid-to-cover ratio of 2.33, below the 10-auction average of 2.35.
European government bond yields moved higher on Monday. The 10-year German bund yield rose +3.9 bp to 3.033%. The 10-year UK gilt yield rose +6.0 bp to 4.972%.
The German May GfK consumer confidence index fell -5.2 to a 3.25-year low of -33.3, weaker than expectations of -30.0.
Swaps are discounting a 6% chance of a +25 bp ECB rate hike at its next policy meeting on Thursday.
US Stock Movers
Health insurance stocks rallied on Monday to provide support to the overall market. Centene (CNC) closed up more than +4%, and Elevance Health (ELV) and Humana (HUM) closed up more than +3%. Also, UnitedHealth Group (UNH) and the Cigna Group (CI) closed up more than +2%, and Cardinal Health (CAH) and Molina Healthcare (MOH) closed up more than +1%.
Airline stocks and cruise line operators fell on Monday after WTI crude oil rose more than +2%, which raises fuel costs and weighs on corporate profits. American Airlines Group (AAL) closed down more than -3%, and Alaska Air Group (ALK), Royal Caribbean Cruises Ltd (RCL), and Southwest Airlines (LUV) closed down more than -2%. Also, United Airlines Holdings (UAL), Carnival (CCL), and Norwegian Cruise Line Holdings Ltd (NCLH) closed down more than -1%, and Delta Air Lines (DAL) closed down -0.37%.
Chipmakers moved lower on Monday, weighing on the broader market. ARM Holdings Plc (ARM) closed down more than -8% to lead losers in the Nasdaq 100. Also, Advanced Micro Devices (AMD), Marvell Technology (MRVL), and Lam Research (LRCX) closed down more than -3%. In addition, Applied Materials (AMAT), Microchip Technology (MCHP), NXP Semiconductors NV (NXPI), KLA Corp (KLAC), and Texas Instruments (TXN) closed down more than -2%, and Analog Devices (ADI) and ASML Holding NV (ASML) closed down more than -1%.
Sandisk (SNDK) closed up more than +8% to lead gainers in the S&P 500 and Nasdaq 100, and Micron Technology (MU) closed up more than +5% after Melius Research LLC initiated coverage on the stocks with buy recommendations.
Stanley Black & Decker (SWK) closed up more than +4% after its board authorized a $500 million stock buyback program.
Verizon Communications (VZ) closed up more than +1% to lead gainers in the Dow Jones Industrials after boosting its full-year adjusted EPS forecast to $4.95-$4.99 from a previous forecast of $4.90-$4.95, stronger than the consensus of $4.90.
Fortinet (FTNT) closed up more than +1% after Arete double-upgraded the stock to buy from sell with a price target of $104.
Crowdstrike Holdings (CRWD) closed up more than +1% after Mizuho Securities upgraded the stock to outperform from neutral with a price target of $520.
VeraDermics (MANE) closed up more than +46% after reporting that its oral extended-release minoxidil formulation VDPHL01 met all primary and key secondary endpoints with high statistical significance in a Phase 2/3 clinical trial for male pattern baldness.
Organon & Co. (OGN) closed up more than +16% after Sun Pharmaceutical Industries Ltd. had lined up a short-term loan to finance its $12 billion acquisition of the company.
Oruka Therapeutics (ORKA) closed up more than +10% after giving positive results from a mid-stage trial of its therapy to treat plaque psoriasis.
Domino’s Pizza (DPZ) closed down more than -8% to lead losers in the S&P 500 after reporting Q1 revenue of $1.15 billion, below the consensus of $1.16 billion.
GE Vernova (GEV) closed down more than -2% after BNP Paribas downgraded the stock to neutral from buy.
Adobe (ADBE) closed down more than -2% after Mizuho Securities downgraded the stock to neutral from outperform.
Earnings Reports(4/28/2026)
Allegion plc (ALLE), American Tower Corp (AMT), Arch Capital Group Ltd (ACGL), Avery Dennison Corp (AVY), Booking Holdings Inc (BKNG), BXP Inc (BXP), Centene Corp (CNC), CMS Energy Corp (CMS), Coca-Cola Co/The (KO), Corning Inc (GLW), CoStar Group Inc (CSGP), Ecolab Inc (ECL), Edison International (EIX), Equity Residential (EQR), Essex Property Trust Inc (ESS), Expand Energy Corp (EXE), Extra Space Storage Inc (EXR), F5 Inc (FFIV), Fair Isaac Corp (FICO), FirstEnergy Corp (FE), Franklin Resources Inc (BEN), General Motors Co (GM), Hilton Worldwide Holdings Inc (HLT), Incyte Corp (INCY), Ingersoll Rand Inc (IR), Invesco Ltd (IVZ), Kimberly-Clark Corp (KMB), Mondelez International Inc (MDLZ), NXP Semiconductors NV (NXPI), Omnicom Group Inc (OMC), ONEOK Inc (OKE), PACCAR Inc (PCAR), Pentair PLC (PNR), PPG Industries Inc (PPG), Robinhood Markets Inc (HOOD), S&P Global Inc (SPGI), Seagate Technology Holdings PL (STX), Sherwin-Williams Co/The (SHW), Starbucks Corp (SBUX), Sysco Corp (SYY), Teradyne Inc (TER), T-Mobile US Inc (TMUS), United Parcel Service Inc (UPS), Veralto Corp (VLTO), Visa Inc (V), Waste Management Inc (WM), Welltower Inc (WELL), Xylem Inc/NY (XYL), Zimmer Biomet Holdings Inc (ZBH).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tech Earnings Optimism Powers Stocks Higher

Humana Inc. HUM is set to report first-quarter 2026 results on April 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $9.97 per share on revenues of $39.5 billion.
The consensus estimate for the first-quarter earnings has increased by 8 cents over the past 30 days. However, the bottom-line projection indicates a year-over-year decrease of 13.9%. The Zacks Consensus Estimate for quarterly revenues implies year-over-year growth of 22.8%.
Image Source: Zacks Investment Research
For full-year 2026, the Zacks Consensus Estimate for Humana’s revenues is pegged at $162.6 billion, implying a rise of 25.3% year over year. Also, the consensus mark for the current year’s EPS is pegged at $9.09, implying a decline of around 47% on a year-over-year basis.
HUM’s earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being 7%.
Humana Inc. Price, Consensus and EPS Surprise
Q1 Earnings Whispers for HUM
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here.
Humana currently has an Earnings ESP of -5.02% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping HUM’s Q1 Results?
Humana's revenue growth in the first quarter is expected to have been supported by higher premiums. The Zacks Consensus Estimate for premiums indicates a 22.2% increase from the prior-year quarter’s reported figure, whereas our model predicts 19.8% growth. Similarly, the consensus mark for service revenues signals a 19.3% increase from a year ago.
The consensus mark for total Medicare revenues signals a 24% increase from a year ago. The Zacks Consensus Estimate for revenues from the CenterWell unit indicates 13.2% growth from a year ago. The Zacks Consensus Estimate for specialty membership is expected to witness nearly 1.6% growth in the quarter under review.
However, the Zacks Consensus Estimate for operating income from the Insurance unit predicts a 15.6% decrease from the year-ago level. Furthermore, the consensus estimate indicates that Humana’s investment income will see a 12.9% drop from the year-ago level.
We expect total operating costs to increase 21.8% in the first quarter, pushing the figure above $36.6 billion. This is likely to have led to a year-over-year decline in the bottom line. The consensus mark for the overall benefits expense ratio is pegged at 89.5% for the to-be-reported quarter, deteriorating from 87% a year ago.
Stocks That Warrant a Look
Here are some companies worth considering from the broader Medical space, as our model shows that these have the right combination of elements to beat on earnings this time:
Agenus Inc. AGEN has an Earnings ESP of +7.69% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Agenus’ bottom line for the to-be-reported quarter indicates 289.3% year-over-year growth. Agenus beat earnings estimates in two of the past four quarters and missed twice, with the average surprise being 31.4%. The consensus estimate for revenues is pegged at $129.5 million.
The Ensign Group, Inc. ENSG presently has an Earnings ESP of +1.12% and a Zacks Rank #2.
The Zacks Consensus Estimate for Ensign Group’s bottom line for the to-be-reported quarter suggests 17.8% year-over-year growth. Ensign Group beat earnings estimates in each of the past four quarters, with the average surprise being 2.9%. The consensus estimate for revenues is pegged at $1.4 billion.
The Cigna Group CI currently has an Earnings ESP of +0.75% and a Zacks Rank of 3.
The Zacks Consensus Estimate for Cigna Group’s earnings for the to-be-reported quarter is pegged at $7.54 per share, suggesting 11.9% year-over-year growth. Cigna Group beat earnings estimates in each of the past four quarters, with the average surprise being 2.7%. The consensus estimate for revenues is pegged at $66.7 billion.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will Increasing Operating Costs Affect Humana's Q1 Earnings?

The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.63%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.42%. June E-mini S&P futures (ESM26) fell -0.62%, and June E-mini Nasdaq futures (NQM26) fell -0.41%.
Stock indexes gave up an early advance on Tuesday and settled lower. Stocks retreated after WTI crude oil rebounded from early losses and rallied more than +2%, when Iran said it won’t attend peace talks in Pakistan before a ceasefire expires on Wednesday.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stock losses accelerated on Tuesday after Vice President Vance's trip to Pakistan to meet Iranian negotiators was put on hold following Iran's failure to respond to US negotiating positions. Also, President Trump said it's "highly unlikely" he will extend the ceasefire with Iran after Wednesday’s deadline, and the US is “ready to go” with a resumption of bombing if a breakthrough isn’t reached.
However, stock index futures recovered in post-market trading after WTI crude oil prices fell, as President Trump, after the markets closed, said he would extend the ceasefire with Iran and maintain the blockade of the Strait of Hormuz, following the scrapping of plans for diplomatic talks between the US and Iran.
Stocks initially moved higher on Tuesday, with the Nasdaq 100 posting a new record high and the Dow Jones Industrial Average hitting a 2-month high on hopes that US-Iran peace talks would continue. Some positive Q1 earnings results from UnitedHealth Group and General Electric also supported stock gains. In addition, Tuesday’s stronger-than-expected US economic reports on March retail sales and March pending home sales suggest that consumer spending is holding up, a supportive factor for stocks.
March retail sales rose +1.7% m/m, stronger than expectations of +1.4% m/m and the biggest increase in a year. Also, March retail sales ex-autos rose +1.9% m/m, stronger than expectations of +1.4% m/m and the biggest increase in 3 years.
US Mar pending home sales rose +1.5%, stronger than expectations of +0.5% m/m.
Meanwhile, stocks found support on signs that Fed Chair nominee Kevin Warsh will back an independent Fed and prioritize low inflation. Fed Chair nominee Warsh's prepared statement before the Senate Banking Committee said he is committed to ensuring that the conduct of monetary policy remains "strictly independent" and to keeping inflation in check, saying price stability is a mandate for the Fed "without excuse or equivocation." When asked if he agreed with President Trump's call for the Fed to lower interest rates, Fed Chair nominee Warsh said, "Unlike many of my colleagues past and present, I don't believe in forward guidance, and I don't believe that I should be previewing for you what a future decision might be."
Senator Tillis of the Senate Banking Committee said he's open to advancing Kevin Warsh's nomination to be Federal Reserve Chair if an ongoing US criminal inquiry into the Fed is dropped and Congress launches its own investigation.
WTI crude oil prices (CLK26) recovered from early losses today and rose more than +2% after Vice President Vance's trip to Pakistan to meet Iranian negotiators was put on hold. The Strait of Hormuz remains essentially closed, threatening to deepen the global energy crisis. The Wall Street Journal reported that the US military is preparing to board Iran-linked oil tankers and seize commercial ships in international waters in the coming days to pressure Iran into reopening the Strait of Hormuz. The blockade could exacerbate global oil and fuel shortages, as about a fifth of the world’s oil and liquefied natural gas transits through the strait. Iran has recently been able to export crude oil during the war, with exports of about 1.7 million bpd in March.
Earnings season continues this week. So far, 83% of the 64 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
The markets are discounting a 1% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.
Overseas stock markets settled mixed on Tuesday. The Euro Stoxx 50 closed down -0.88%. China's Shanghai Composite rose to a 1-month high and closed up +0.07%. Japan's Nikkei Stock 225 closed up +0.89%.
Interest Rates
June 10-year T-notes (ZNM6) on Tuesday closed down by -11.5 ticks. The 10-year T-note yield rose by +3.3 bp to 4.284%. T-notes retreated on Tuesday amid stronger-than-expected US economic reports on Mar retail sales and Mar pending home sales. T-notes added to their losses on Tuesday after WTI crude oil recovered from early losses and rallied by more than +2%, which lifted inflation expectations and is bearish for T-note prices.
T-notes have support on signs that Fed Chair nominee Kevin Warsh will support an independent Fed and prioritize low inflation. Fed Chair nominee Warsh's prepared statement before the Senate Banking Committee said he is committed to ensuring that the conduct of monetary policy remains "strictly independent" and to keeping inflation in check, saying price stability is a mandate for the Fed "without excuse or equivocation."
European government bond yields moved higher on Tuesday. The 10-year German bund yield rose by +2.4 bp to 3.004%. The 10-year UK gilt yield climbed to a 1-week high of 4.892% and finished up by +5.0 bp to 4.884%.
The German Apr ZEW survey expectations of economic growth fell -16.7 to a 3.25-year low of -17.2, weaker than expectations of -5.8.
Swaps are discounting a 13% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.
US Stock Movers
Cryptocurrency-exposed stocks moved lower on Tuesday as Bitcoin (^BTCUSD) fell more than -2%. Coinbase Global (COIN) closed down more than -7%, and Galaxy Digital Holdings (GLXY) closed down more than -6%. Also, Strategy (MSTR) and Riot Platforms (RIOT) closed down more than -4%, and MARA Holdings (MARA) closed down more than -3%.
Alaska Air Group (ALK) closed down more than -4% to lead airline stocks lower after crude prices rose more than +2%, boosting fuel costs, and after the company forecast a Q2 adjusted loss per share of -$1.00, much wider than the consensus of -11 cents, and announced that it will suspend full-year guidance due to higher fuel costs. Also, United Airlines Holdings (UAL) and American Airlines Group (AAL) closed down more than -3%, and Southwest Airlines (LUV) closed down more than -2%. In addition, Delta Air Lines (DAL) closed down more than -1%.
Mining stocks slumped on Tuesday as gold prices fell more than -2% and silver prices fell more than -4%. Coeur Mining (CDE) and Hecla Mining (HL) closed down more than -6%, and Anglogold Ashanti (AU) and Barrick Mining (B) closed down more than -5%. Also, Newmont Corp (NEM) closed down more than -4%, and Freeport McMoRan (FCX) closed down more than -3%.
UnitedHealth Group (UNH) closed up more than +7% to lead health insurance stocks higher after reporting Q1 adjusted EPS of $9.23, well above the consensus of $6.57, and raising its full-year adjusted EPS estimate to above $18.25 from a previous view of $17.75. Humana (HUM) closed up more than +4% on the news, Centene (CNC) and Elevance Health (ELV) closed up more than +2%, and CVS Health (CVS) closed up more than +1%.
Cybersecurity stocks moved higher on Tuesday, lending support to the broader market. CrowdStrike Holdings (CRWD) closed up more than +3% to lead gainers in the Nasdaq 100. Also, Palo Alto Networks (PANW), Fortinet (FTNT), and Zscaler (ZS) closed up more than +3%. In addition, Okta (OKTA) closed up more than +2%, and Cloudflare (NET) closed up more than +1%.
Tractor Supply Co (TSCO) closed down more than -11% to lead losers in the S&P 500 after reporting Q1 net sales of $3.59 billion, below the consensus of $3.64 billion.
Northrop Grumman (NOC) closed down more than -6% after forecasting full-year adjusted EPS of $27.40 to $27.90, below the consensus of $27.97.
Prudential Financial (PRU) closed down more than -5% after Nikkei reported that former employees of the company’s Gibraltar business are suspected of committing dozens of cases of financial fraud.
Merk & Co (MRK) closed down more than -3% to lead losers in the Dow Jones Industrials after its Phase 3 trial with Eisai for treatment of advanced renal cell carcinoma did not meet its dual primary endpoints.
Avis Budget Group (CAR) closed up more than +17% amid a short squeeze as two investors, SRS Investment Management and Pentwater Capital Management, own about 71% of the company’s shares. According to S3 Partners data, the company's short interest as a percentage of its free float is currently 62%.
Northern Trust (NTRS) closed up more than +8% to lead gainers in the S&P 500 after reporting Q1 net interest income FTE of $661.6 million, above the consensus of $627.6 million.
D.R. Horton (DHI) closed up more than +5% after reporting Q2 net sales orders of 24,992, better than the consensus of 23,919, and raising its full-year revenue forecast to $34.5 billion from a previous estimate of $33.5 billion to $35.0 billion, stronger than the consensus of $33.4 billion.
Quest Diagnostics (DGX) closed up more than +4% after reporting Q1 net revenue of $2.90 billion, better than the consensus of $2.82 billion.
Arrowhead Pharmaceuticals (ARWR) closed up more than +2% after Morgan Stanley upgraded the stock to overweight from equal weight with a price target of $100.
Earnings Reports(4/22/2026)
AT&T Inc (T), Boeing Co/The (BA), Boston Scientific Corp (BSX), CME Group Inc (CME), Crown Castle Inc (CCI), CSX Corp (CSX), Elevance Health Inc (ELV), GE Vernova Inc (GEV), Globe Life Inc (GL), International Business Machine (IBM), Kinder Morgan Inc (KMI), Lam Research Corp (LRCX), Las Vegas Sands Corp (LVS), Masco Corp (MAS), Moody's Corp (MCO), NVR Inc (NVR), Otis Worldwide Corp (OTIS), Packaging Corp of America (PKG), Philip Morris International Inc (PM), Raymond James Financial Inc (RJF), Rollins Inc (ROL), ServiceNow Inc (NOW), Southwest Airlines Co (LUV), TE Connectivity PLC (TEL), Teledyne Technologies Inc (TDY), Tesla Inc (TSLA), Texas Instruments Inc (TXN), United Rentals Inc (URI), Vertiv Holdings Co (VRT), Westinghouse Air Brake Technol (WAB).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Fall as Iran Refuses to Attend Peace Talks

The S&P 500 Index ($SPX) (SPY) today is down -0.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.02%. June E-mini S&P futures (ESM26) are down -0.13%, and June E-mini Nasdaq futures (NQM26) are up +0.05%.
Stock indexes gave up an early advance and turned mixed today as WTI crude oil rebounded from early losses, jumping more than +2%, amid market speculation about whether Iran will take part in a second round of talks before a ceasefire expires on Wednesday.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stocks initially moved higher today, with the Nasdaq 100 posting a new record high and the Dow Jones Industrial Average hitting a 2-month high. Iran initially said it was sending a team to Pakistan for the negotiations, though it wasn’t clear who would be on the team or when they would arrive. President Trump said Vice President Vance would resume negotiations in person, “either Tuesday night or Wednesday morning,” and it's "highly unlikely" he will extend the ceasefire with Iran after Wednesday’s deadline.
Some positive Q1 earnings results from UnitedHealth Group and General Electric are also supporting stock gains. In addition, today’s stronger-than-expected US economic reports on March retail sales and March pending home sales suggest that consumer spending is holding up, a supportive factor for stocks.
March retail sales rose +1.7% m/m, stronger than expectations of +1.4% m/m and the biggest increase in a year. Also, March retail sales ex-autos rose +1.9% m/m, stronger than expectations of +1.4% m/m and the biggest increase in 3 years.
US Mar pending home sales rose +1.5%, stronger than expectations of +0.5% m/m.
Market attention will be on Capitol Hill today as Kevin Warsh appears before the Senate Banking Committee for a confirmation hearing for his nomination as the new Fed Chair. Senator Thom Tillis, a member of the Banking Committee, has said he won’t vote for Warsh until the Department of Justice (DOJ) ends its investigation into a building renovation project at the Fed, which current Fed Chair Powell has said is really a political attack on the Fed over interest rates. Tillis can block Warsh’s nomination from advancing to the full Senate, and neither President Trump nor the DOJ has shown any sign they will close the investigation.
WTI crude oil prices (CLK26) recovered from early losses today and are up more than +2% as Iran has yet to confirm its attendance in Pakistan for peace talks with the US before a ceasefire expires on Wednesday. The Strait of Hormuz remains essentially closed, threatening to deepen the global energy crisis. The Wall Street Journal reported that the US military is preparing to board Iran-linked oil tankers and seize commercial ships in international waters in the coming days to pressure Iran into reopening the Strait of Hormuz. The blockade could exacerbate global oil and fuel shortages, as about a fifth of the world’s oil and liquefied natural gas transits through the strait. Iran has recently been able to export crude oil during the war, with exports of about 1.7 million bpd in March.
Earnings season continues this week. So far, 81% of the 48 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
The markets are discounting a 1% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.
Overseas stock markets are mixed today. The Euro Stoxx 50 is down -0.87%. China's Shanghai Composite rose to a 1-month high and closed up +0.07%. Japan's Nikkei Stock 225 closed up +0.89%.
Interest Rates
June 10-year T-notes (ZNM6) today are down by -11 ticks. The 10-year T-note yield is up +3.9 bp to 4.290%. T-notes are sliding today on stronger-than-expected US economic reports on Mar retail sales and Mar pending home sales. T-notes added to their losses today after WTI crude oil recovered from early losses and rallied by more than +2%, which lifted inflation expectations and is bearish for T-note prices.
T-notes have support on signs that Fed Chair nominee Kevin Warsh will support an independent Fed and prioritize low inflation. Fed Chair nominee Warsh's prepared statement before the Senate Banking Committee said he is committed to ensuring that the conduct of monetary policy remains "strictly independent" and to keeping inflation in check, saying price stability is a mandate for the Fed "without excuse or equivocation."
European government bond yields are moving higher today. The 10-year German bund yield is up +1.6 bp to 2.996%. The 10-year UK gilt yield is up +3.4 bp to 4.868%.
The German Apr ZEW survey expectations of economic growth fell -16.7 to a 3.25-year low of -17.2, weaker than expectations of -5.8.
Swaps are discounting a 9% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.
US Stock Movers
UnitedHealth Group (UNH) is up more than +7% to lead health insurance stocks higher after reporting Q1 adjusted EPS of $9.23, well above the consensus of $6.57, and raising its full-year adjusted EPS estimate to above $18.25 from a previous view of $17.75. Humana (HUM) is also up more than +5% on the news, Centene (CNC) and Elevance Health (ELV) are up more than +2%, and CVS Health (CVS) is up +1%.
Cybersecurity stocks are moving higher today, lending support to the broader market. Zscaler (ZS) is up more than +5% to lead gainers in the Nasdaq 100. Also, CrowdStrike Holdings (CRWD) is up more than +4%, and Okta (OKTA) and Palo Alto Networks (PANW) are up more than +3%. In addition, Fortinet (FTNT) is up more than +2%, and Cloudflare (NET) is up more than +1%.
Software stocks are stronger today, a positive factor for the overall market. Atlassian (TEAM), ServiceNow (NOW), and Cadence Design Systems (CDNS) are up more than +3%. Also, Workday (WDAY), Salesforce (CRM), Intuit (INTU), Datadog (DDOG), and Oracle (ORCL) are up more than +2%. In addition, Autodesk (ADSK) and Microsoft (MSFT) are up more than +1%.
Amazon.com (AMZN) is up more than 1% after it said it is investing an additional $5 billion in Anthropic and may inject $20 billion more over time. Amazon’s suppliers are also climbing on the news, with Astera Labs (ALAB) up more than +7%, and Marvell Technology (MRVL) and Credo Technology (CRDO) are up more than +1%.
Avis Budget Group (CAR) is up more than +9% amid a short squeeze as two investors, SRS Investment Management and Pentwater Capital Management, own about 71% of the company’s shares. According to S3 Partners data, the company's short interest as a percentage of its free float is currently 62%.
D.R. Horton (DHI) is up more than +7% after reporting Q2 net sales orders of 24,992, better than the consensus of 23,919, and raising its full-year revenue forecast to $34.5 billion from a previous estimate of $33.5 billion to $35.0 billion, stronger than the consensus of $33.4 billion.
Northern Trust (NTRS) is up more than +5% after reporting Q1 net interest income FTE of $661.6 million, above the consensus of $627.6 million.
Quest Diagnostics (DGX) is up more than +4% after reporting Q1 net revenue of $2.90 billion, better than the consensus of $2.82 billion.
Arrowhead Pharmaceuticals (ARWR) is up more than +3% after Morgan Stanley upgraded the stock to overweight from equal weight with a price target of $100.
Intel (INTC) is up more than +1% after HSBC upgraded the stock to buy from hold with a price target of $95.
Tractor Supply Co (TSCO) is down more than -8% to lead losers in the S&P 500 after reporting Q1 net sales of $3.59 billion, below the consensus of $3.64 billion.
Northrop Grumman (NOC) is down more than -6% after forecasting full-year adjusted EPS of $27.40 to $27.90, below the consensus of $27.97.
Merk & Co (MRK) is down more than -4% to lead losers in the Dow Jones Industrials after its Phase 3 trial with Eisai for treatment of advanced renal cell carcinoma did not meet its dual primary endpoints.
Prudential Financial (PRU) is down more than -4% after Nikkei reported that former employees of the company’s Gibraltar business are suspected of committing dozens of cases of financial fraud.
Alaska Air Group (ALK) is down more than -4% after forecasting a Q2 adjusted loss per share of -$1.00, much wider than the consensus of -11 cents, and announcing that it will suspend full-year guidance due to higher fuel costs.
Earnings Reports(4/21/2026)
3M Co (MMM), Capital One Financial Corp (COF), Chubb Ltd (CB), Danaher Corp (DHR), DR Horton Inc (DHI), EQT Corp (EQT), Equifax Inc (EFX), General Electric Co (GE), Genuine Parts Co (GPC), Halliburton Co (HAL), Interactive Brokers Group Inc (IBKR), Intuitive Surgical Inc (ISRG), MSCI Inc (MSCI), Northern Trust Corp (NTRS), Northrop Grumman Corp (NOC), Quest Diagnostics Inc (DGX), RTX Corp (RTX), Synchrony Financial (SYF), Tractor Supply Co (TSCO), United Airlines Holdings Inc (UAL), UnitedHealth Group Inc (UNH), W R Berkley Corp (WRB).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	25.95 21.97
Price/Sales	0.18 3.13
P/B	1.67 2.24
P/FCF	20.17 18.90

Indicator	TTM Median
ROE	7.26 24.62
ROA	2.38 6.73
ROI	3.87 9.85
Net Worth	22.93 0.21
Quick Ratio	0.00 1.72
Current Ratio	0.74 2.84

Indicator	TTM Median
Net Profit Margin	0.92 11.21
Operating Margin	2.09 14.57
Gross Margin	36.69 69.23
Return on tangible equity	15.83 54.38

Indicator	TTM Median
EPS	-3.96 0.37
EPS Forecast	-4.01 0.37
Revenue	32.65B 16.00M
Gross Profit	32.52B —
EBITDA	604.00M —

Humana Inc.

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue